Xadcera Biopharmaceutical (suzhou) Co., Ltd.

This early-phase study tests a new drug called DM002 in 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by testing low to higher doses in small groups; second, giving t…